Nimotuzumab consists of the active Nimotuzumab. It is a monoclonal antibody used in cancer treatment.  It has been approved for the treatment of head and neck cancer, as well as for certain types of brain cancer. This medication is typically used with other cancer treatments, such as chemotherapy and radiation therapy. 

There are no absolute contraindications to Nimotuzumab, but there are some precautions and potential contraindications to consider. For example, patients with a history of severe allergic reactions or hypersensitivity to it or its components should not receive the medication. Additionally, patients with certain medical conditions, such as severe liver or kidney disease, may need to be monitored closely or have their dosages adjusted.

Nimotuzumab is used in the treatment of several types of cancer, including head and neck cancer and certain types of brain cancer, such as glioma and glioblastoma. It is often combined with other cancer treatments, such as chemotherapy and radiation therapy, to improve overall and disease-free outcomes.

Nimotuzumab is an injectable medication that a healthcare professional administers. It is typically given as an intravenous injection. The dose and frequency will depend on the type of cancer being treated, the patient's overall health, and other medications the patient may be taking.  If you miss a dose, contact your healthcare provider as soon as possible. Your healthcare provider may recommend rescheduling your next dose or adjusting your dosing schedule. Do not double the dose to make a missed dose.

Nimotuzumab, like all medications, can cause side effects. These side effects can vary in severity and frequency from person to person. Common side effects are infusion reactions, such as fever, chills, nausea, and vomiting, as well as skin reactions, such as rash, itching, and dry skin. Fatigue or weakness, headache, changes in taste or appetite, and pain or swelling at the injection site are also common side effects. In rare cases, it can cause more serious side effects. These may include an allergic reaction, such as difficulty breathing, hives, or swelling of the face or throat, decrease in white blood cells, or platelets. Other serious side effects include severe skin reactions.

Nimotuzumab may cause infusion reactions, which can include fever, chills, nausea, vomiting, or difficulty breathing. These reactions typically occur during or shortly after the infusion, and your healthcare provider may monitor you closely during the treatment. It may cause skin reactions like rash, itching, or dry skin. In rare cases, this medication causes severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Some patients may be allergic to this medication, which can cause symptoms such as difficulty breathing, hives, or swelling of the face or throat. It may cause a decrease in white blood cells or platelets, which can increase the risk of infection or bleeding. It can also cause pulmonary embolism, blood clots, and increased risk of heart attack.

Before taking nimotuzumab, it is important to inform your healthcare provider of any previous allergic reactions to medications or other substances and any medications or supplements you are currently taking. It may cause a decrease in white blood cells or platelets, which can increase the risk of infection or bleeding, and your healthcare provider may monitor your blood cell counts during treatment. Additionally, it can harm an unborn baby or pass into breast milk, so women of reproductive age should avoid pregnancy and breastfeeding while taking this medication. Reproductive-age women should avoid pregnancy. If you have any concerns or questions about taking this medication, it is important to discuss them with your healthcare provider.

It is important to carefully read the medication label before taking Nimotuzumab. Follow the instructions provided by your healthcare provider and the label, such as how much to take and how often. Your healthcare provider can provide more information on the risks and benefits of it and can help you determine if it is the right treatment option for you. It is important to report any side effects you may experience during treatment to your healthcare provider. Pregnancy and breastfeeding are not recommended while taking this medication. Before starting it or any other medication, inform your healthcare provider of any allergies or medications you are taking. This can help prevent any potential interactions or adverse effects.

1. KD Tripathi, Essentials of Medical Pharmacology, 7th edition, Jaypee Brothers Medical Publishers (P) Ltd.; 2013, 893-894.
2. Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton, L.L., Chabner, B.A., and Knollmann, B.C., eds.). Nimotuzumab. 13th edition, 1461-1463.
3. Bespons Pvt Ltd,  U.S. Food and Drug Administration., Highlights of prescribing information - Nimotuzumab, [Last updated: March 2020],[10 April 2023], Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
4. S.H. Ibbotson, R.S. Dawe, Skin Disease, Davidson’s Principles & Practice of Medicine, 22nd Edition, 2014, 1249-1305

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.